| http://www.w3.org/ns/prov#value | - Incidence by protocol was: 14% for MDX-010 and vaccine (melanoma patients); 20% for MDX-010 dose escalation with or without vaccine (melanomapatients); and 28% for MDX-010 alone (no dose escalation) (renal cell carcinoma patients).Presenting Symptoms: Patients presented with symptoms including abdominal pain, nausea and vomiting, fever, anal pain, and diarrhea.
|
